The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

Author:

van Asten FreekjeORCID,Michels Charlotte T. J.,Hoyng Carel B.,van der Wilt Gert Jan,Klevering B. Jeroen,Rovers Maroeska M.,Grutters Janneke P. C.

Funder

Radboud Institute for Health Sciences

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Why have UK doctors been deterred from prescribing Avastin?;D Cohen;BMJ,2015

2. National Institute for Health Care Excellence (NICE). Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, 2008.

3. National Institute for Health Care Excellence (NICE). Aflibercept solution for injection for treating wet age-related macular degeneration, 2013.

4. Office of Inspector General. Medicare Payments for Drugs Used to Treat Wet Age-Related Macular Degeneration. OEI-03-10-00360. Department of Health and Human Services, Washington DC, 2012.

5. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis;WL Wong;Lancet Glob Health,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3